Your browser doesn't support javascript.
loading
Ant venom immunotherapy in Australia: the unmet need.
Mullins, Raymond J; Brown, Simon G A.
Affiliation
  • Mullins RJ; John James Medical Centre, Canberra, ACT, Australia. simon.brown@uwa.edu.au.
  • Brown SG; University of Western Australia and Royal Perth Hospital, Perth, WA, Australia.
Med J Aust ; 201(1): 33-4, 2014 Jul 07.
Article in En | MEDLINE | ID: mdl-24999895
ABSTRACT
Jack jumper ant (JJA) venom allergy is an important cause of anaphylaxis in south-eastern Australia. The efficacy and real-world effectiveness of JJA venom immunotherapy (VIT) to prevent anaphylaxis in allergic patients are now well established, with an evidence base that is at least equivalent to that supporting VIT for allergy to other insect species. The tolerability and safety of JJA VIT are comparable with those of honeybee VIT.
Subject(s)
Search on Google
Add to My VHL
Print
XML
PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Desensitization, Immunologic / Health Services Needs and Demand / Hypersensitivity / Anaphylaxis / Ant Venoms Type of study: Etiology_studies / Risk_factors_studies Limits: Humans Country/Region as subject: Oceania Language: En Journal: Med J Aust Year: 2014 Document type: Article Affiliation country:
Search on Google
Add to My VHL
Print
XML
PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Desensitization, Immunologic / Health Services Needs and Demand / Hypersensitivity / Anaphylaxis / Ant Venoms Type of study: Etiology_studies / Risk_factors_studies Limits: Humans Country/Region as subject: Oceania Language: En Journal: Med J Aust Year: 2014 Document type: Article Affiliation country: